Note 9 - Collaborative and Other Research and Development Contracts (Details) (USD $)	6 Months Ended	1 Months Ended	12 Months Ended	1 Months Ended		12 Months Ended	1 Months Ended			50 Months Ended	9 Months Ended
	Jun. 30, 2006	Feb. 28, 2006	Dec. 31, 2012	May 31, 2010	Jun. 30, 2000	Dec. 31, 2014	Feb. 24, 2011	Sep. 30, 2009	Jan. 31, 2007	Feb. 24, 2011	Sep. 30, 2014	Dec. 31, 2007	Nov. 11, 2011
UpFront Payment [Member] | Mundipharma [Member]
Note 9 - Collaborative and Other Research and Development Contracts (Details) [Line Items]
Deferred Revenue		$ 10,000,000
2007 Clinical Trial [Member] | Mundipharma [Member]
Note 9 - Collaborative and Other Research and Development Contracts (Details) [Line Items]
Deferred Revenue												5,000,000
Green Cross Corporation [Member]
Note 9 - Collaborative and Other Research and Development Contracts (Details) [Line Items]
Proceeds from License Fees Received	250,000
Mundipharma [Member]
Note 9 - Collaborative and Other Research and Development Contracts (Details) [Line Items]
Upfront Payments Receivable Amount		10,000,000
Potential Milestone Payments Receivable													15,000,000
Unamortized Deferred Revenue Related To Amended And Restated Agreement			7,766,000
Unamortized Deferred Expenses Related To Amended And Restated Agreement			1,864,000
AECOM and IRL [Member]
Note 9 - Collaborative and Other Research and Development Contracts (Details) [Line Items]
Milestone Payment Minimum						1,400,000
Milestone Payment Maximum						4,000,000
Annual License Fee Minimum						150,000
Annual License Fee Maximum						500,000
Advance Notice Period for Termination of Agreement					60 days
Stock Issued During Period Value for Modification of License Agreement				5,911,000
Payments for Modification of License Agreement				90,000
U.S. Department of Health and Human Services [Member]
Note 9 - Collaborative and Other Research and Development Contracts (Details) [Line Items]
Collaborative Agreement Contract Value									102,661,000
Collaborative Agreement Additional Contract Value							55,000,000	77,191,000
Collaborative Agreement Adjusted Contract Value										234,852,000
National Institute of Allergy and Infectious Diseases [Member]
Note 9 - Collaborative and Other Research and Development Contracts (Details) [Line Items]
Proceeds from Awards for Research and Development Contracts						5,000,000,000
Expected Receivable from Awards for Research and Development Contracts						28,717,000,000
Collaborative Agreement Period of Contract						5 years
Collaboration Agreement Additional Payments Received						$ 22,302,000,000
UAB [Member]
Note 9 - Collaborative and Other Research and Development Contracts (Details) [Line Items]
Number of Agreements						2
Period of Agreement											25 years